EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyse

Clinical Potential of Mirtazapine in Anxiety and Trauma‐Related Disorders: A Systematic Review and Meta‐Analysis of Current Evidence

Claudio Caiazza iD, Vito Rago, Niccolò Solini, Luigi Franzese, Francesco Lusciano, Domenico Mazza, Claudia Rago

Human Psychopharmacology: Clinical and Experimental · 2026-03 · 41 (2)

DOI: 10.1002/hup.70037 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Human Psychopharmacology: Clinical and Experimental, online erschienen am 12.03.2026. Verfasst von Claudio Caiazza und 6 weiteren Autor:innen. Beteiligte Einrichtung: Azienda Sanitaria Locale Napoli 3 Sud, Unità Operativa Centro di Salute Mentale 55-57 Torre del Greco-Ercolano, Naples, Italy. Hauptthemen laut MEDLINE: Mirtazapine, Major Depressive Disorder, Anxiety Disorders, Stress Disorders, Post-Traumatic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 77 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Mirtazapine is a noradrenergic and specific serotonergic antidepressant (NaSSA) with sedative features that may be advantageous for anxiety and trauma‐related disorders, yet its role remains unclear.

Methods

We systematically reviewed and meta‐analyzed the evidence on mirtazapine in anxiety disorders, major depressive disorder evaluating anxious symptoms, and trauma‐related disorders, following PRISMA guidelines. Following a pre‐registered protocol ( https://osf.io/562zj/?view_only=0f596df97bc74b2bb25ebbf1dcbd7589 ), we searched PubMed/EMBASE/CENTRAL/ClinicalTrials.gov/WHO‐ICTRP from inception until 07/07/2025. The co‐primary outcomes were efficacy (symptom decrease—Standardized Mean Difference/SMD and response—Risk Ratio/RR) and acceptability.

Results

Out of 799 identified records, 37 studies were included. In generalized anxiety disorder (GAD), mirtazapine paralleled selective serotonin reuptake inhibitors (SSRIs) (SMD = −0.14, 95% C.I. [−0.38, 0.09], p = 0.23, I 2 = 13.3%, τ 2 = 0.01, k = 5, n = 330), benzodiazepines (SMD = −0.03, 95% C.I. [−0.83, 0.77], p = 0.94, I 2 = 85.9%, τ 2 = 0.43, k = 4, n = 233). In major depressive disorder (MDD), mirtazapine slightly outperformed SSRIs regarding anxiety (SMD = −0.16, 95% C.I. [−0.25, 0.07], p < 0.01, I 2 = 0%, τ 2 = 0, k = 10, n = 1732), and paralleled tricyclic antidepressants (TCAs). In post‐traumatic stress disorder, SSRI augmentation was effective. Acceptability was comparable to placebo and SSRIs.

Discussion

Mirtazapine was more effective than SSRIs for anxiety in MDD and may be preferred when anxiety is relevant. In GAD, mirtazapine may serve as an alternative to first‐line agents, and further regulatory explorations are warranted. In PTSD, mirtazapine has potential as an augmentation strategy. Mirtazapine was generally well tolerated and may be advantageous for patients requiring rapid effect or relief from sleep disturbances.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MirtazapineMajor Depressive DisorderAnxiety DisordersStress Disorders, Post-TraumaticHumansGeneralized Anxiety DisorderSelective Serotonin Reuptake Inhibitors

Stichwörter der Autor:innen

anxietycomorbiditymirtazapinerepurposingsedativetrauma

Substanzen

MirtazapineSelective Serotonin Reuptake Inhibitors

Autor:innen und Institutionen

  • Azienda Sanitaria Locale Napoli 3 Sud, Unità Operativa Centro di Salute Mentale 55-57 Torre del Greco-Ercolano, Naples, Italy.
  • Department of Pharmacy, University of Naples, Federico II, Naples, Italy.

ORCID-Profile: Claudio Caiazza

Zitieren

APA

Caiazza, C., Rago, V., Solini, N., Franzese, L., Lusciano, F., Mazza, D., & Rago, C. (2026). Clinical Potential of Mirtazapine in Anxiety and Trauma‐Related Disorders: A Systematic Review and Meta‐Analysis of Current Evidence. Human Psychopharmacology: Clinical and Experimental, 41(2). https://doi.org/10.1002/hup.70037

Vancouver

Caiazza C, Rago V, Solini N, Franzese L, Lusciano F, Mazza D, et al. Clinical Potential of Mirtazapine in Anxiety and Trauma‐Related Disorders: A Systematic Review and Meta‐Analysis of Current Evidence. Human Psychopharmacology: Clinical and Experimental. 2026;41(2). doi:10.1002/hup.70037

BibTeX
@article{Caiazza2026,
  author = {Caiazza, Claudio and Rago, Vito and Solini, Niccolò and Franzese, Luigi and Lusciano, Francesco and Mazza, Domenico and Rago, Claudia},
  title = {Clinical Potential of Mirtazapine in Anxiety and Trauma‐Related Disorders: A Systematic Review and Meta‐Analysis of Current Evidence},
  journal = {Human Psychopharmacology: Clinical and Experimental},
  year = {2026},
  volume = {41},
  number = {2},
  doi = {10.1002/hup.70037}
}
Kostenlos starten →